Bio-Path Holdings, Inc. (BPTH) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BPTH representa a Bio-Path Holdings, Inc., una empresa del sector Healthcare con un precio de $0.05 (capitalización de mercado 416K). Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 15 mar 2026Bio-Path Holdings, Inc. (BPTH) Resumen de Asistencia Médica y Tuberías
Bio-Path Holdings, Inc. is a biotechnology company specializing in RNAi nanoparticle drug development for oncology, utilizing its proprietary DNAbilize platform. With drug candidates in Phase 1 and 2 clinical trials targeting AML, lymphoma, and solid tumors, Bio-Path seeks to improve treatment efficacy and delivery in the competitive biotechnology landscape.
Tesis de Inversión
Bio-Path Holdings operates in the high-risk, high-reward biotechnology sector, with a focus on RNAi nanoparticle drug development. The company's lead drug candidate, Prexigebersen (BP1001), is in Phase 2 clinical trials for AML, representing a key value driver. Successful trial outcomes and subsequent regulatory approvals could significantly increase the company's value. Further potential lies in the development of BP1001-A and other pipeline assets targeting solid tumors and hematologic malignancies. However, the company faces significant risks associated with clinical trial failures, regulatory hurdles, and the need for substantial capital to fund ongoing research and development. The company's market capitalization is $0.00B as of March 15, 2026.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Bio-Path Holdings is focused on RNAi nanoparticle drug development for oncology.
- The company's lead drug candidate, Prexigebersen (BP1001), is in Phase 2 clinical trials for the treatment of untreated acute myeloid leukemia (AML).
- BP1001-A is in Phase 1 clinical trials for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer.
- Liposomal Bcl-2 (BP1002) is in Phase 1 clinical trials to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia.
- Liposomal STAT3 (BP1003) is in preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML.
Competidores y Pares
Fortalezas
- Proprietary DNAbilize platform.
- Pipeline of drug candidates in various stages of development.
- Focus on targeted therapies for cancer.
- Experienced management team.
Debilidades
- Limited financial resources.
- Dependence on clinical trial outcomes.
- High risk of drug development failure.
- OTC market listing.
Catalizadores
- Ongoing: Phase 2 clinical trial results for Prexigebersen (BP1001) in AML.
- Ongoing: Phase 1 clinical trial progress for BP1001-A in solid tumors.
- Upcoming: Potential partnerships or collaborations with pharmaceutical companies.
- Upcoming: Publication of preclinical data for Liposomal STAT3 (BP1003).
- Upcoming: Regulatory updates regarding drug development programs.
Riesgos
- Ongoing: Clinical trial failures or delays.
- Ongoing: Regulatory setbacks or rejection of drug candidates.
- Potential: Need for additional capital to fund operations.
- Potential: Competition from other cancer therapies.
- Potential: Intellectual property challenges or patent infringement.
Oportunidades de crecimiento
- Expansion of Prexigebersen (BP1001) into additional AML subtypes: The market for AML therapies is substantial, and Bio-Path could expand the use of Prexigebersen into additional AML subtypes beyond untreated AML. This would require further clinical trials but could significantly increase the drug's market potential. The AML therapeutics market is projected to reach $4.2 billion by 2027, offering a substantial opportunity for Bio-Path.
- Advancement of BP1001-A in solid tumor indications: BP1001-A is currently in Phase 1 clinical trials for solid tumors, including ovarian, endometrial, and pancreatic cancer. Successful clinical trial outcomes could lead to regulatory approvals and commercialization in these indications. The global solid tumor market is expected to reach $450 billion by 2030, presenting a significant growth opportunity for Bio-Path.
- Development of Liposomal Bcl-2 (BP1002) for lymphoma and CLL: Liposomal Bcl-2 is in Phase 1 clinical trials for refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia. Positive clinical data could lead to further development and commercialization in these hematologic malignancies. The lymphoma and CLL therapeutics market is projected to reach $25 billion by 2028.
- Preclinical development of Liposomal STAT3 (BP1003) for various cancers: Liposomal STAT3 is in preclinical development for pancreatic cancer, non-small cell lung cancer, and AML. Successful preclinical studies could lead to clinical trials and potential commercialization in these indications. The market for pancreatic cancer therapeutics is projected to reach $4.5 billion by 2027.
- Partnerships and collaborations: Bio-Path could pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's growth prospects. Strategic alliances are common in the biotechnology industry and can significantly de-risk development programs.
Oportunidades
- Expansion into new cancer indications.
- Partnerships with larger pharmaceutical companies.
- Advancement of preclinical programs into clinical trials.
- Potential for breakthrough therapies in oncology.
Amenazas
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Need for significant capital to fund development.
Ventajas competitivas
- Proprietary DNAbilize platform for drug delivery.
- Patent protection for drug candidates and platform technology.
- Clinical trial data demonstrating safety and efficacy.
- Expertise in RNAi technology and nanoparticle formulation.
Acerca de BPTH
Bio-Path Holdings, Inc., founded in 2007 and based in Bellaire, Texas, is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. The company is dedicated to developing innovative therapies for cancer using its proprietary DNAbilize platform. This platform utilizes P-ethoxy, a deoxyribonucleic acid (DNA) backbone modification designed to protect DNA from enzymatic degradation in vivo, encapsulated within a neutral-charge lipid bilayer. Bio-Path's lead drug candidate, Prexigebersen (BP1001), is currently in Phase 2 clinical trials for the treatment of untreated acute myeloid leukemia (AML). The company is also advancing BP1001-A, which is in Phase 1 clinical trials for solid tumors, including ovarian, endometrial, and pancreatic cancer. Furthermore, BP1001-A is in preclinical development for treating obesity and related metabolic diseases. Other pipeline assets include Liposomal Bcl-2 (BP1002), in Phase 1 clinical trials for refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia, and Liposomal STAT3 (BP1003), in preclinical development for pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path's focus on RNAi technology and nanoparticle drug delivery positions it within the evolving landscape of targeted cancer therapies.
Qué hacen
- Develops RNAi nanoparticle drugs for cancer treatment.
- Utilizes the DNAbilize platform for drug delivery.
- Conducts clinical trials for various cancer indications.
- Focuses on targeted therapies for improved efficacy.
- Develops treatments for both hematologic malignancies and solid tumors.
- Engages in preclinical research for new drug candidates.
Modelo de Negocio
- Develops and patents RNAi nanoparticle drug candidates.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from agencies like the FDA.
- Potentially commercializes approved drugs or partners with larger pharmaceutical companies.
Contexto de la Industria
Bio-Path Holdings operates within the biotechnology industry, which is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Bio-Path are focused on developing targeted therapies that offer improved efficacy and reduced toxicity compared to traditional treatments. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in specific cancer indications. Success in this industry requires significant investment in research and development, as well as the ability to navigate complex regulatory pathways.
Clientes Clave
- Patients with cancer, including AML, lymphoma, and solid tumors.
- Hospitals and oncology clinics.
- Potential pharmaceutical partners for licensing and collaboration agreements.
Finanzas
Gráfico e información
Precio de la acción de Bio-Path Holdings, Inc. (BPTH): $0.05 (-0.00, -5.66%)
Últimas noticias
-
US Stocks Mixed; NY State Business Activity Rises In February
benzinga · 18 feb 2025
-
94 Biggest Movers From Yesterday
· 11 feb 2021
-
Stocks That Hit 52-Week Lows On Monday
· 16 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BPTH.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BPTH.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BPTH en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de BPTH
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bio-Path Holdings may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, early-stage ventures, or those that choose not to meet the requirements for higher tiers.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure.
- Higher potential for fraud or manipulation.
- Greater price volatility.
- Lower liquidity.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the company's capital structure and ownership.
- Review any independent audits or reports.
- Consult with a qualified financial advisor.
- Presence of a professional website and investor relations materials.
- Independent directors or advisors.
- History of regulatory compliance.
- Audited financial statements (if available).
- Active communication with shareholders.
BPTH Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar BPTH?
Bio-Path Holdings, Inc. (BPTH) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Proprietary DNAbilize platform.. Riesgo principal a monitorear: Ongoing: Clinical trial failures or delays.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BPTH?
BPTH actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BPTH?
Los precios de BPTH se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BPTH?
La cobertura de analistas para BPTH incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BPTH?
Las categorías de riesgo para BPTH incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Clinical trial failures or delays.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BPTH?
La relación P/E para BPTH compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BPTH sobrevalorada o infravalorada?
Determinar si Bio-Path Holdings, Inc. (BPTH) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BPTH?
Bio-Path Holdings, Inc. (BPTH) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than major exchange data.